Jazz Pharmaceuticals plc 4

Executive Chairman Bruce C. Cozadd disposed of a total of 7,219 Jazz Pharmaceuticals ordinary shares, primarily to cover tax obligations from RSU vesting, including a 6,000‑share sale under a Rule 10b5‑1 plan.

On this Form 4, Jazz Pharmaceuticals plc Executive Chairman Bruce C. Cozadd reported two small tax-related share withholdings on August 31, 2026 and one larger tax-related sale on September 1, 2026. On August 31, 10 and 1,209 ordinary shares, respectively, were withheld/disposed of at prices of approximately $244.06 and $241.39 per share in connection with the vesting of previously granted restricted stock units, both coded as transaction type F (payment of exercise/vesting price or tax liability by delivering or withholding securities). On September 1, 2026, he sold 6,000 ordinary shares at $250.13 per share, with the footnote stating these were sold to satisfy tax obligations from RSU vesting and executed automatically under a pre‑arranged Rule 10b5‑1 trading plan. Following these transactions, Cozadd’s direct holdings declined from 359,084 shares before the first withholding to 351,875 shares after the sale, representing an estimated post‑transaction equity value in the high‑double‑digit millions of dollars range based on the indicated trading prices.

Filing Facts

CIK

1232524

Ticker

JAZZ

Form

4

Source Type

fda

Accession

0001193210-26-000025

Alert Tier

6